Tissue Regenix plans a 2018 launch for dCELL® decellularization technology in the U.S. for orthopaedic applications, initially addressing anterior cruciate ligament repair.
dCELL is a multi-tissue regenerative platform using animal and human biological materials from which DNA and other cellular material are removed, leaving the acellular scaffold intact. This scaffold provides support for cell migration during the healing process, while preserving tissue strength.
EU clinical trials are underway for the evaluation of the dCELL scaffold for reconstruction of the anterior cruciate ligament; estimated primary completion date is February 2018. The company will share information on this progress while attending the 2017 American Academy of Orthopedic Surgeons (AAOS) annual meeting.
Tissue Regenix plans a 2018 launch for dCELL® decellularization technology in the U.S. for orthopaedic applications, initially addressing anterior cruciate ligament repair.
dCELL is a multi-tissue regenerative platform using animal and human biological materials from which DNA and other cellular material are removed, leaving the acellular...
Tissue Regenix plans a 2018 launch for dCELL® decellularization technology in the U.S. for orthopaedic applications, initially addressing anterior cruciate ligament repair.
dCELL is a multi-tissue regenerative platform using animal and human biological materials from which DNA and other cellular material are removed, leaving the acellular scaffold intact. This scaffold provides support for cell migration during the healing process, while preserving tissue strength.
EU clinical trials are underway for the evaluation of the dCELL scaffold for reconstruction of the anterior cruciate ligament; estimated primary completion date is February 2018. The company will share information on this progress while attending the 2017 American Academy of Orthopedic Surgeons (AAOS) annual meeting.
Copy to clipboard 
